Program
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001
Also written as “SKB264+SKB118”, “CR-001” and “SKB118 Injection”.
Its studies are mostly in Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Drug pageAnti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Kelun Pharmaceuticalits history only | 33 open or running | phase 2since May 7, 2026 | May 7, 2026 | Dec 30, 2027phase 2 · NCT07854509 |
| Crescent Biopharmaits history only | 11 open or running | phase 2since Jan 8, 2026 | Jan 8, 2026 | Feb 2029phase 2 · NCT07335497 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 8, 2026First study: phase 2 study in Neoplasm MetastasisNew to Crescent BiopharmaCrescent Biopharma · NCT07335497 · 540 planned · United States, Australia, France and more
- May 7, 2026Sichuan Kelun Pharmaceutical’s first study: phase 2 study in Advanced Solid TumorsNew to Sichuan Kelun PharmaceuticalSichuan Kelun Pharmaceutical · NCT07586943 · 530 planned · China
- Jul 3, 2026Phase 2 study in NSCLCSichuan Kelun Pharmaceutical · NCT07697586 · 206 planned · China
- Sep 28, 2026Phase 2 study in Non-Squamous Non-Small Cell Lung CancerSichuan Kelun Pharmaceutical · NCT07854509 · 110 planned
Ahead
- Dec 30, 2027Primary completion: phase 2 study in Non-Squamous Non-Small Cell Lung CancerSichuan Kelun Pharmaceutical · NCT07854509
- Aug 2028Primary completion: phase 2 study in NSCLCSichuan Kelun Pharmaceutical · NCT07697586
- Feb 2029Primary completion: phase 2 study in Neoplasm MetastasisCrescent Biopharma · NCT07335497
- Dec 2029Primary completion: phase 2 study in Advanced Solid TumorsSichuan Kelun Pharmaceutical · NCT07586943
TargetBeta
“A tetravalent bispecific antibody consisting of a bivalent, Fc-silenced, immunoglobulin G1 (IgG1) antibody targeting human vascular endothelial growth factor A (VEGF-A), with two single chain variable fragments (scFvs) targeting the negative immunoregulatory human cell receptor programmed cell death”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| tivunatamig | Pfizer | phase 3 | 15 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010 | Merck | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039Arule | Minghui Pharmaceutical | phase 2 | 3 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rule | wigen-biomedicine-technology-shanghai-co-ltd | phase 2 | 2 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rule | compass-therapeutics | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07854509Non-Squamous Non-Small Cell Lung Cancer | 2 | Not yet recruiting | Sichuan Kelun Pharmaceutical | Dec 30, 2027 | 110 |
| NCT07697586NSCLC · China | 2 | Recruiting | Sichuan Kelun Pharmaceutical | Aug 2028 | 206 |
| NCT07586943Advanced Solid Tumors · China | 2 | Recruiting | Sichuan Kelun Pharmaceutical | Dec 2029 | 530 |
| NCT07335497Neoplasm Metastasis · United States, Australia, France and more | 2 | Recruiting | Crescent Biopharma | Feb 2029 | 540 |
How it is read
Names in the registry
- “SKB264+SKB118”, 2 entries
- “CR-001”, 1 entry
- “SKB118 Injection”, 1 entry
- “SKB118+SKB264”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.